US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
ドイツ
TG
Mediclin (MED) 銘柄情報

Mediclin (MED)

4.10

0.06

( 1.49% )

更新日時： 00:35:44

Mediclin (MED) 銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

4.10

( 1.49% )

買値

3.96

売値

4.18

出来高

540

4.08 日の範囲 4.18

2.80 52 週間の範囲 4.28

時価総額

前日終値

4.04

始値

4.18

時刻

最終取引時間

21:01:19

財務取引量

-

VWAP

-

平均取引量 (3 か月)

10,654 €

発行済株式数

47,500,000

配当利回り

0.04 (1.09%)

PER

6.62

1 株当たり利益 (EPS)

0.61

歳入

810.48M

純利益

29.18M

MEDICLIN Aktiengesellschaft operates hospitals in Germany. The company operates through Post-Acute; Acute; and Nursing Care and Service segments. It offers medical services in the areas of neurology; psychosomatics; orthopedics; internal medicine; cardiology; oncology; geriatrics; psychiatry; otorhi... MEDICLIN Aktiengesellschaft operates hospitals in Germany. The company operates through Post-Acute; Acute; and Nursing Care and Service segments. It offers medical services in the areas of neurology; psychosomatics; orthopedics; internal medicine; cardiology; oncology; geriatrics; psychiatry; otorhinolaryngology; cardiac medicine; rheumatology; gynecology; trauma, heart, and general surgeries; urology; and others. The company also provides services in the areas of ENT and acute outpatient services. It owns 31 clinical facilities, rehabilitation care, 6 nursing care facilities, and 9 medical care centers in 11 German federal states. The company was incorporated in 1994 and is headquartered in Offenburg, Germany. 詳細を表示

セクター

Healthcare

業界

Healthcare Providers & Services

ウェブサイト

www.mediclin.de

本社

Offenburg, Germany

設立

1994

Mediclin is listed in the Healthcare sector of the Tradegate (DE) with ticker MED. The last closing price for Mediclin was 4.04 €. Over the last year, Mediclin shares have traded in a share price range of 2.80 € to 4.28 €.

Mediclin currently has 47,500,000 shares in issue. The market capitalisation of Mediclin is 194.75 € million. Mediclin has a price to earnings ratio (PE ratio) of 6.62.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.1600001	-3.75587089202	4.26	4.26	3.96	6615	4.15153439	DE
4	0.5399999	15.1685365169	3.56	4.28	3.52	5769	3.86579621	DE
12	0.4999999	13.8888861111	3.6	4.28	3.32	4825	3.64792342	DE
26	0.2999999	7.89473421053	3.8	4.28	3.32	3875	3.66603403	DE
52	1.1199999	37.5838892617	2.98	4.28	2.8	3172	3.48637979	DE
156	1.1199999	37.5838892617	2.98	4.28	2.2	2358	3.19326993	DE
260	-0.1800001	-4.20560981308	4.28	4.28	2.2	1811	3.2772874	DE

MED - Frequently Asked Questions (FAQ)

What is the current Mediclin share price?

The current share price of Mediclin is 4.10 €

How many Mediclin shares are in issue?

Mediclin has 47,500,000 shares in issue

What is the market cap of Mediclin?

The market capitalisation of Mediclin is EUR 194.75M

What is the 1 year trading range for Mediclin share price?

Mediclin has traded in the range of 2.80 € to 4.28 € during the past year

What is the PE ratio of Mediclin?

The price to earnings ratio of Mediclin is 6.62

What is the cash to sales ratio of Mediclin?

The cash to sales ratio of Mediclin is 0.24

What is the registered address of Mediclin?

The registered address for Mediclin is Okenstr. 27, Offenburg, Baden-Württemberg, 77652

What is the Mediclin website address?

The website address for Mediclin is www.mediclin.de

Which industry sector does Mediclin operate in?

Mediclin operates in the Healthcare Providers & Services sector

Slojab

News. Such as it is.

https://www.otcmarkets.com/stock/QEDN/news/QED-Connect-Inc-OTCID-QEDN-is-pleased-to-announce-its-strategic-collaboration-withGMSacha-Inchiand-the-La-Palmichala-Pro?id=525065

joe botts

joe botts 3分前

Why dont you try it? Oh sorry I forgot my role here as a paid pumper.

rack186

rack186 4分前

But... The Mikah issue will always be a road block, no matter how attractive things may appear. This probably has already factored into " thanks, but we're not interested"

Krombacher

Krombacher 4分前

Following up on my own concession, because I want to be precise about what I
gave you and what I didn't.

I granted — and still grant — that once a DBMM trade routes out to a US market
and settles through NSCC, your chain holds: the US clearing member borrows,
d

price_and_volume

price_and_volume 4分前

Newbie retail buying-the-open often peters-out here...

GLTA!

Stonkey Kong64

Stonkey Kong64 4分前

we thinking we're seeing anything here this week?

thundersteel

thundersteel 5分前

To me, some parts of the website look updated

and seems to run faster, than before. Was this number posted on the site an Indian phone number or United States?

+1 617-701-7683

Thanks gg

TS

Hoghead7

Hoghead7 5分前

The daily chart is trending as I hoped and looks like we might get that 5% I suggested earlier. At the very least it looks like it'll close over $17.50 unless there's a reversal for whatever reason. I expect we are much closer to that $30 price target from Canacord Then those other revised targets

linkvest

linkvest 5分前

New MM on the ASK.. AEXG

jtomm

VRXAW - It sounds like the other issue is the warrants can't be exercised yet. Not until 30 days after the deal, which Grok guesses puts it at around July 8th. In the meantime the merger docs apparently mentioned the possibility of EXTREME dilution, due to additional financings, PIPE deals, etc.

PavilionInvestor

PavilionInvestor 5分前

One11

Why is that? Is it because they don't care? Is it because it's not really needed? It's baffling that this is taken so long to get any kind of worthy news or any kind of confirmation of possible partnerships, contracts, or even just to get trials completed so that we can see the results. Something is

Overwatch

Overwatch 6分前

Very weird volume here....

rich2

Some of the same bashers
have been trying to bash NBRI for more than a year

liftoff is soon to happen

Covid19freak

Covid19freak 6分前

BFRI $1 FDA DECISION in September while valued at laughable 12 million dollar

"FDA's completion of its filing review and filing acceptance of the Company's supplemental New Drug Application (sNDA) for Ameluz PDT for the treatment of superficial basal cell carcinoma (sBCC), with a PDUF

iamadog

iamadog 7分前

It just takes a CEO like Melvin who does what he says to give us a life changing opportunity . We are here for a multitude of reasons . Actually not we are on this train until we decide to leave . Today perfect example of what buying at the ask does for price . I was majority for a reason . I know t

Covid19freak

Covid19freak 7分前

BFRI $1 FDA DECISION in September while valued at laughable 12 million dollar

"FDA's completion of its filing review and filing acceptance of the Company's supplemental New Drug Application (sNDA) for Ameluz PDT for the treatment of superficial basal cell carcinoma (sBCC), with a PDUF

timberwolf7

timberwolf7 7分前

Have to laugh at this commentary with respect to SPCX

with the potential to "achieve a similar growth trajectory to SPCX over time."

spcx is going to need to have a spectacular growth trajectory for quite a while to start to get
close to justifying its share p

TheKid5

TheKid5 8分前

The pain is always worse the next day

linkvest

linkvest 8分前

Nice dip before we hit $200

Porch Honkey

Porch Honkey 8分前

Yeah I smell it too and stinks read bad, lol.

CommodityCoverage

CommodityCoverage 8分前

Posted on behalf of Selkirk Copper Mines – In a new shareholder letter, Selkirk Copper (SCMI.v SKRKF) CEO Colin Joudrie detailed the company's "first nation advantage" in advancing the Minto Copper-Gold-Silver Mine in Yukon: https://x.com/StckMasterFlash/status/2066589136832938021

Wit

FeMike

Without ILT's guidance I'm completely lost

I was just pondering on this, I've so missed updates on how much our stock is worth on the LSE and our weekly renewing targets for the floodgates opening.

marylandstockguy

marylandstockguy 8分前

Why don’t you try it? Oh sorry I forgot my role here

iShares ESG Aware 80/20 ...

GLOBAL X AGTECH & FOOD I...

Barclays Bank Plc Capped...

Almacenes Exito

Amundi US Treasury Bond ...

Renaissance Money Market...

Vontobel Financial Produ...

0.125% 4sep2026

Colruyt Group NV

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。